Arovella Therapeutics (ASX:ALA) – tackling blood cancers and solid tumours
15 Nov 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company.
15Nov
15Nov
OncoSil Medical (ASX:OSL) – targeted therapy for pancreatic cancer
15 Nov 2022 - OncoSil Medical Limited (ASX:OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company's therapy.
11Nov
K2fly (ASX:K2F) – providing ESG solutions for top 50 mining companies
11 Nov 2022 - K2fly Limited (ASX:K2F) CEO Nic Pollock discusses K2F's progress and milestones over the past year.
04Nov
Chimeric Therapeutics (ASX:CHM) enters research agreement to advance cell therapy portfolio
04 Nov 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses the company's new agreement with Case Western Reserve University.
03Nov
Antisense Therapeutics (ASX:ANP) appoints Chief Commercial Officer
03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.
02Nov
Novonix (ASX:NVX) receives US$150m grant for EV battery production
02 Nov 2022 - Novonix Limited (ASX:NVX) CEO Dr Chris Burns discusses news following the company's AGM, including the appointment of new directors and the expansion of the company's development capabilities.
31Oct
Market update with Shaw and Partners, October 2022
31 Oct 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the market outlook, giving general advice on investment implications.
27Oct
icetana (ASX:ICE) discusses Macnica deal and new product launch
27 Oct 2022 - icetana Limited (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses the company's recent deal with Japanese group Macnica and the launch of a new product.
12Oct
Immutep (ASX:IMM) receives fast track designation from FDA
12 Oct 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company's new Phase 2 trial in soft tissue sarcoma and the outlook ahead.
12Oct
Technology giant Macnica takes strategic investment in icetana (ASX:ICE)
12 Oct 2022 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses revenue growth, the company's strategic placement to Macnica, changes to the share registry and the outlook ahead.